TherapeuticsMD
TXMD
146 hedge funds and large institutions have $948M invested in TherapeuticsMD in 2016 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 56 increasing their positions, 38 reducing their positions, and 20 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 38
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
7% more funds holding
Funds holding: 137 → 146 (+9)
0.09% more ownership
Funds ownership: 1.58% → 1.67% (+0.09%)
8% less call options, than puts
Call options by funds: $3.79M | Put options by funds: $4.12M
10% less capital invested
Capital invested by funds: $1.05B → $948M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$34.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$20.3M |
| 3 |
JP Morgan Chase
New York
|
+$15.9M |
| 4 |
Millennium Management
New York
|
+$10.7M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$48.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.91M |
| 3 |
D.E. Shaw & Co
New York
|
-$4.87M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$2.72M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.7M |
TXMD Hedge Fund Activity: Q4 2016 in Review
146 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2016, worth a combined $948M — down 9.9% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new TXMD positions and 20 closed out — a net gain of 9 holders — while 56 added to existing stakes and 38 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $34.3M. The largest seller was Wellington Management Group, cutting an estimated $48.5M.
- 146 institutional investors held TherapeuticsMD (TXMD) as of Q4 2016, up from 137 in Q3 2016.
- Funds reported $948M of TherapeuticsMD stock for Q4 2016, down 9.9% quarter-over-quarter.
- 29 funds opened new TherapeuticsMD positions in Q4 2016 and 20 closed out, a net change of +9 holders.
- The largest TherapeuticsMD buyer in Q4 2016 was Bank of New York Mellon, an estimated $34.3M added.
- The largest TherapeuticsMD seller in Q4 2016 was Wellington Management Group, an estimated $48.5M sold.
Based on aggregated 13F filings for Q4 2016.